Precision BioSciences Reports Strong Q1 Revenue Growth, Reduced Operating Loss, and Key Clinical Milestones

summarizeSummary

Precision BioSciences reported a significant increase in Q1 revenue and a reduced net loss, driven by clinical milestone achievements. The company also reaffirmed its cash runway through 2028 and announced key regulatory and clinical advancements for its lead gene editing programs.

check_boxKey Events

• Significant Revenue Growth

  Revenue for Q1 2026 increased to $10.8 million, up from less than $0.1 million in Q1 2025, primarily due to a $7.5 million clinical milestone payment from TG Therapeutics and a $4.0 million milestone from an agriculture collaboration.

• Reduced Net Loss and Operating Cash Burn

  The net loss decreased to $(18.4) million in Q1 2026 from $(20.6) million in Q1 2025. Cash used in operating activities significantly decreased to $(11.9) million from $(19.1) million in the prior year period.

• Reaffirmed Cash Runway

  Management believes existing cash and cash equivalents, coupled with fiscal discipline and the ATM facility, will fund operating expenses and capital expenditure requirements through 2028.

• FDA Fast Track Designation for PBGENE-DMD

  The PBGENE-DMD program for Duchenne muscular dystrophy received FDA Fast Track designation in March 2026, potentially accelerating its development and review process.

auto_awesomeAnalysis

Precision BioSciences reported significant financial and clinical progress in its first-quarter 2026 results. Revenue surged to $10.8 million, a substantial increase from the prior year, driven by a $7.5 million clinical milestone payment from TG Therapeutics and a $4.0 million milestone from an agriculture collaboration. The company also successfully reduced its net loss and significantly decreased cash used in operating activities. Crucially, management reaffirmed its cash runway through 2028, supported by existing cash and its at-the-market (ATM) facility. On the clinical front, the company announced FDA Fast Track designation for PBGENE-DMD and CTA approval to expand the ELIMINATE-B trial for PBGENE-HBV into Europe, signaling accelerated development and broader reach for its lead programs. These positive developments, including strategic prioritization of its core gene editing programs, indicate strong operational execution and a strengthened financial position for future development.